Celcuity (CELC) reported a Q3 adjusted loss late Wednesday of $0.78 per diluted share, wider than a loss of $0.65 a year earlier.
Three analysts expected a loss of $0.96 in a FactSet poll.
The clinical-stage biotechnology company said it has funds to run its operations through 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.